Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

[1]  D. Sugarbaker,et al.  Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Scagliotti,et al.  Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Rabin,et al.  Patient Subsets Benefiting from Adjuvant Therapy Following Surgical Resection of Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[4]  D. Galetta,et al.  O-090 Weekly vinorelbine plus cisplatin versus day 1+8 vinorelbine withcisplatin in advanced non small cell lung cancer: End results of a phase III trial , 2005 .

[5]  G. Strauss.  Adjuvant chemotherapy of lung cancer: methodologic issues and therapeutic advances. , 2005, Hematology/oncology clinics of North America.

[6]  K. Matsuo,et al.  Role of Adjuvant Chemotherapy in Patients With Resected Non-Small-Cell Lung Cancer: Reappraisal With a Meta-analysis of Randomized Controlled Trials , 2006 .

[7]  T. Treasure,et al.  Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. , 2004, The Journal of thoracic and cardiovascular surgery.

[8]  M. Parmar,et al.  Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. , 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[9]  M. Taulelle.  Une chimiothérapie adjuvante par mitomycine, cisplatine et vindésine n’améliore pas la survie de cancers bronchiques non à petites cellules opérés , 2004 .

[10]  H. Kato,et al.  A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. , 2004, The New England journal of medicine.

[11]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[12]  G. Giaccone,et al.  Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. , 2003, Journal of the National Cancer Institute.

[13]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[14]  R. Livingston,et al.  [A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer]. , 2001, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[15]  W. Fry,et al.  Ten‐year survey of lung cancer treatment and survival in hospitals in the United States , 1999, Cancer.

[16]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[17]  C. Mountain,et al.  Value of the New TNM Staging System for Lung Cancer , 1989 .

[18]  N. Hanna,et al.  Vinorelbine Plus Cisplatin vs Observation in Resected Non–Small-Cell Lung Cancer , 2006 .